- Home
- GRCE vs STTK Comparison
GRCE vs STTK Comparison
Compare GRCE & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRCE
- STTK
- Stock Information
- Founded
- GRCE 2002
- STTK 2016
- Country
- GRCE United States
- STTK United States
- Employees
- GRCE N/A
- STTK N/A
- Industry
- GRCE
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- GRCE
- STTK Health Care
- Exchange
- GRCE NYSE
- STTK Nasdaq
- Market Cap
- GRCE 40.0M
- STTK 37.6M
- IPO Year
- GRCE N/A
- STTK 2020
- Fundamental
- Price
- GRCE $3.00
- STTK $0.96
- Analyst Decision
- GRCE Strong Buy
- STTK Hold
- Analyst Count
- GRCE 1
- STTK 4
- Target Price
- GRCE $12.00
- STTK $3.00
- AVG Volume (30 Days)
- GRCE 40.7K
- STTK 116.5K
- Earning Date
- GRCE 08-15-2025
- STTK 07-31-2025
- Dividend Yield
- GRCE N/A
- STTK N/A
- EPS Growth
- GRCE N/A
- STTK N/A
- EPS
- GRCE N/A
- STTK N/A
- Revenue
- GRCE N/A
- STTK $4,606,000.00
- Revenue This Year
- GRCE N/A
- STTK N/A
- Revenue Next Year
- GRCE N/A
- STTK N/A
- P/E Ratio
- GRCE N/A
- STTK N/A
- Revenue Growth
- GRCE N/A
- STTK 69.65
- 52 Week Low
- GRCE $1.75
- STTK $0.69
- 52 Week High
- GRCE $4.97
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- GRCE N/A
- STTK 44.24
- Support Level
- GRCE N/A
- STTK $0.95
- Resistance Level
- GRCE N/A
- STTK $1.24
- Average True Range (ATR)
- GRCE 0.00
- STTK 0.08
- MACD
- GRCE 0.00
- STTK -0.02
- Stochastic Oscillator
- GRCE 0.00
- STTK 5.05
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.